May 8, 2019 Maria Ohle

BioTime Stock: “Buy” Ratings Abound, Should You Take Note?

BioTime Stock

BioTime stock is currently selling for $1.18 USD on the NYSE American exchange. At the time of writing, shares are down nearly 5%. Despite a rough few trading days, BTX stock has a consensus rating of “Buy” from six analysts.

So let’s check this out.

BioTime Stock

BioTime Inc (NYSE:BTX) is a clinical-stage biotechnology company developing treatments for several degenerative diseases. Headquartered in California, the company’s flagship products include OpRegen, a treatment aimed at macular degeneration of the eye, which is synonymous with the elderly, OPC1, which is a treatment for acute spinal cord injuries, and VAC2, a treatment aimed at non-small cell lung cancer.

OpRegen and OPC1 are both in trial Phase I/IIa, and VAC2 is in Phase I.

BioTime Stock on the Rise

Despite a volatile April, BioTime stock has gained 35.82% since the beginning of the year. Further, it has a consensus price target of $4.86—more than 400% of its current value. Analysts are screaming “Buy” on this stock, and it could be because the company showed promise in its most recent earnings results in March.

>> HCLP Stock Plunges 17%: Hi-Crush Reports Larger than Expected Loss

The biotechnology company reported $0.07 earnings per share, which matched the consensus estimate. Further, it had revenue of $0.76 million for the quarter, which beat analysts’ expectations of $0.74 million.

Now, it is set to announce its latest earnings results after the market closes tomorrow, Thursday, May 9.

Major Institutional Investors Boost Stake

With major institutional investors reportedly upping their stake in BioTime, investors are being given plenty of signs. The following investors recently increased their holdings of BioTime stock:

  • BlackRock Inc boosted holdings by 3.1% in Q3
  • Geode Capital Management increased holdings by 3.1% in Q4
  • Virtu Financial boosted holdings by a whopping 165.4% in Q4; the company increased its stake to 34,884 shares.

Other boosts include Teachers Advisors LLC (20%), Vanguard Group (0.6%), and Rhumbline Advisers (43.7%).

So with analysts bullish on BioTime stock and a consensus price target 400% above its current value, it could be safe to assume BTX shares are showing undervalued signals.

What do you think?

>> Read More Biotech News

Featured Image: DepositPhotos © baranq

Please See Disclaimer


STOCKS YOU MAY LIKE


Risks and Disclosure:

Information provided in this correspondence is intended solely for informational purposes and is obtained from sources believed to be reliable. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained on this website is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions made or suggested and the actual results.

All statements and opinions expressed are the opinions of the author and not of Microsmallcap.com or its officers. The author is wholly responsible for the validity of all statements. Microsmallcap.com was not involved in any aspect of the article preparation. The author was not paid by Market Jar Media Inc for this article. The author did not pay Microsmallcap.com to publish or syndicate this article.

This article does not constitute as investment advice. Each reader is encouraged to consult with his or her individual financial advisor; any and all actions taken by a reader as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Microsmallcap.com's terms of use and full legal disclaimer. This article is in no way a solicitation for investment. Microsmallcap.com does not render general or specific investment advice. Any information on Microsmallcap.com should not be considered a recommendation to buy or sell any security. Microsmallcap.com does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks, and options may fluctuate, and, as a result, clients may lose more than their original investment and possibly their entire investment. Any content on this website should not be relied upon as advice or construed as providing recommendations of any kind. It is your responsibility to confirm and decide which trades to make. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Please see our full disclaimer here for additional details before making any investment decisions.